News & Updates
Filter by Specialty:
Post-treatment HBsAg loss greater with TDF vs entecavir
In patients with chronic hepatitis B (CHB) without cirrhosis, the rates of hepatitis B surface antigen (HBsAg) loss appear to be higher after discontinuation of tenofovir disoproxil fumarate (TDF) than of entecavir, and this is particularly true for patients who have not experienced relapse after treatment discontinuation, according to a study.
Post-treatment HBsAg loss greater with TDF vs entecavir
12 Jun 2023
Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK
For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.
Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK
12 Jun 2023
Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC
In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.
Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC
12 Jun 2023
Add-on myoinositol helps with menstrual period regularity in women with PCOS
In the treatment of women with polycystic ovary syndrome (PCOS), adding myoinositol to metformin provides further benefits for improving the regularity of menstrual cycle, with subsequent gains in quality of life, according to a study.
Add-on myoinositol helps with menstrual period regularity in women with PCOS
12 Jun 2023
Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC
Patients with nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation appear to experience similar survival outcomes with either frontline osimertinib therapy or sequential treatment approach of gefitinib followed by osimertinib, although upfront osimertinib leads to a significant reduction in the risk of brain progression, as shown in the results of the APPLE trial presented at ELCC 2023.
Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC
10 Jun 2023
Nonchemotherapy doublet shows therapeutic potential in PD-1/PD-L1 inhibitor‒resistant NSCLC
Combination treatment with eftilagimod alpha plus pembrolizumab has shown promising signal of activity against metastatic nonsmall cell lung cancer (NSCLC) in patients resistant to PD-1/PD-L1 inhibitors, as shown in the updated results of the phase II TACTI-002 study.
